4SC AG: 4SC announces Half-Year Report 2024 and provides update
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
In einer Welt, in der die Digitalisierung im Gesundheitssektor unaufhaltsam voranschreitet, steht die Frage im Mittelpun…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
Katairo GmbH, a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for ba…
Der Umgang mit hochsensiblen Patienten- und Kundendaten gehört für den Reha-Spezialisten interco Group! zum täglichen Ge…
Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international r…
First patient with Pectus Excavatum congenital defect has undergone surgery in Australia Minimally invasive procedure an…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…